Pain relief associated with decreased oxyhemoglobin level in left dorsolateral prefrontal cortex

Shun Miyashiro\(^1\), Yurika Yamada\(^1\), Masaru Nagaoka\(^1\), Rei Shima\(^1\), Toshizumi Muta\(^2\), Haruyuki Ishikawa\(^3\), Tetsuri Abe\(^2\), Masashi Hori\(^4\), Kotaro Oka\(^5,6,7\), Fusako Koshikawa\(^2\), Etsuro Ito\(^1,6,7\)*

\(^1\) Department of Biology, Waseda University, Tokyo, Japan, \(^2\) Department of Psychology, Waseda University, Tokyo, Japan, \(^3\) Department of Culture, Media and Society, Waseda University, Tokyo, Japan, \(^4\) Department of Educational Psychology, Waseda University, Tokyo, Japan, \(^5\) Department of Bioscience and Informatics, Keio University, Yokohama, Japan, \(^6\) Waseda Research Institute for Science and Engineering, Waseda University, Tokyo, Japan, \(^7\) Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

☯ These authors contributed equally to this work.
* eto@waseda.jp

Abstract

Pain in the elbow, shoulder, knee, lower back, and various other joints is relieved by adhesion of pyramidal thorn patches. To elucidate the pain relief mechanism induced by the patches, we established a quantitative method for estimating the pain reduction and investigated the brain regions that change in association with pain relief. We first attempted to quantify the pain relief using transcutaneous electric stimulation (TCES) and a visual analog scale (VAS), and then applied near-infrared spectroscopy (NIRS) to the prefrontal cortex, including the dorsolateral prefrontal cortex (DLPFC) and the orbitofrontal cortex (OFC). We also examined the salivary oxytocin levels, which are thought to reflect oxytocin secretion levels from the posterior pituitary in the brain. Application of pyramidal thorn patches to pain regions decreased the pain degree estimated using TCES and VAS. Oxyhemoglobin levels were likely to be decreased in the left DLPFC on the basis of NIRS measurements during patch treatment, suggesting that the left DLPFC is involved in pain relief. On the other hand, the salivary oxytocin levels varied widely. A potential reason for the varying salivary oxytocin levels is its utilization in the pain region as an analgesic agent. Our results suggest that the left DLPFC will become a target brain region for pain therapy.

Introduction

Pain relief is highly sought after, especially by those with chronic pain. Recognition of the limitations of commercially available analgesic drugs has led to an increased use of complementary and integrative health approaches (e.g., natural products, deep breathing, meditation, massage, etc.) for various types of pain, such as back pain, neck pain, and joint pain [1]. One integrative approach is therapeutic touch. Saito et al. recently developed a circular adhesive patch with a
silicone spine shaped like a pyramidal thorn [2, 3], called a pyramidal thorn patch. Application of pyramidal thorn patches to various pain regions in 300 patients relieved pain in almost all the patients within 4 treatments [2]. In these studies, the degree of pain relief was estimated using a visual analog scale (VAS).

The prefrontal cortex is strongly implicated as a brain region involved in the modulation of both nociception and antinociception [4]. The prefrontal cortex has connections with the insular cortex and medial thalamic nuclei, which are involved in nociception modulation [5–7]. The medial prefrontal cortex receives ascending nociceptive input, but also exerts important top-down control of pain sensation [8]. The medial prefrontal cortex has sustained tonic facilitatory action (i.e., a noxious thermally-evoked response) over the thalamic centralis lateralis nucleus [9]. The prefrontal cortex is also thought to function in antinociception through connections with the amygdala and periaqueductal grey matter [10–12]. For example, the pathways from the basolateral nucleus of amygdala to the prefrontal cortex inhibit nociceptive cell activities in the prefrontal cortex [13]. We thus hypothesized that observing changes in prefrontal cortex activation offers the opportunity to clarify pain relief mechanisms in the brain.

Near-infrared spectroscopy (NIRS) is a useful, noninvasive method for measuring changes in brain activity [14]. NIRS measures oxyhemoglobin and deoxyhemoglobin concentrations at the brain surface in real-time [15]. NIRS overcomes many problems of other brain imaging techniques, such as functional magnetic resonance imaging (fMRI) or positron emission tomography (PET), including concerns about participant posture, spatial resolution, time resolution, loud sounds, and the need for a shielded room [16]. When NIRS is applied to the prefrontal cortex, activity changes are easily observed as a change in oxyhemoglobin concentrations [15]. Thus, NIRS is useful for exploring brain regions in the prefrontal cortex involved in pain relief.

The effect of oxytocin for pain relief should also be considered [17–19]. Oxytocin is a peptide hormone comprising 9 amino acids, and is synthesized in neurons of the supraoptic nucleus and paraventricular nucleus of the hypothalamus after specific stimulation of the brain [20]. These neurons project to the posterior pituitary, where oxytocin is released into the blood for delivery to peripheral tissues as well as into the brain [21, 22]. Oxytocin has antinociceptive effects [23, 24], but the molecular and cellular mechanisms of pain relief by oxytocin have not been established. We hypothesized that oxytocin secretion is increased during pain relief [19].

In the present study, we first attempted to establish a quantitative method for measuring pain reduction by application of pyramidal thorn patches using transcutaneous electric stimulation (TCES). Changes in oxyhemoglobin levels before and after pain relief in the prefrontal cortex were then examined by NIRS. Finally, salivary oxytocin levels were measured during pain relief by enzyme-linked immunosorbent assay (ELISA). The present study provides insight into both the use of NIRS for quantifying pain relief and the role of oxytocin in pain relief.

Materials and methods

Ethics statement

The present study was carried out in accordance with the recommendations of the principles and guidelines of the Declaration of Helsinki. All participants provided written informed consent to participate in the present study. A questionnaire was distributed to the participants to inquire about the pain regions in the body and the time elapsed from the onset of pain. The protocol was approved by the academic research ethics review committee of Waseda University, Office of Research Ethics (2016–282, 2018–067, 2021–018).
Participants

Two groups of participants were enrolled. The first group comprised 18 voluntary participants from the Tokyo area in Japan who did not have pain on the basis of self-assessment (no-Pain group; age 18–29 years; 10 men and 8 women; all right-handed). The second group comprised 27 voluntary participants who declared themselves to have pain on the basis of self-assessment (Pain group; age 19–25 years; 10 men and 17 women; all right-handed). The pain regions in these participants were as follows: shoulder joint (n = 13); lower back (n = 11); knee joint (n = 1); sternum (n = 1); and left wrist (n = 1). Each participant in the Pain group stated the type of posture that produced the pain.

Treatment with the pyramidal thorn patch

The pyramidal thorn patch was developed by Saito and colleagues [2, 3]. The detailed method for the patch treatment was described previously [3]. Briefly, the pyramidal thorn patch is a circular adhesive patch (3 cm in diameter and 0.1-mm thick) made of synthetic resin (Fig 1). The center of the circular patch is made of low-density polyethylene in a 7-mm square area and the tapered pyramidal thorn is 3 mm high. To determine where to place the pyramidal thorn patches, the experimenters used strong thumb pressure to palpate the skin surface of the pain region and its surrounding area indicated by the participant. After the experimenters determined the pain location, several pyramidal thorn patches were adhered in the region. For the Pain group, 15–20 pyramidal thorn patches were adhered to the pain regions; and for the no-Pain group, approximately 15 patches were adhered over the shoulder joint. The duration of patch treatment was about 30 min.

Pain measurements by TCES and VAS

Before and after patch treatment, the degree of pain was determined using a TCES and VAS. The directions of posture that produced the pain were given to the participants in the Pain group with an audio guide. The TCES (Pain Vision, PS 2100, NIPRO, Osaka, Japan) shows the ‘pain degree’ that can be calculated from the current perception threshold, defined as the lowest electrical current detected by participants, and the pain-compatible electrical current, defined by the electrical current judged by each participant as being compatible with the intensity of ongoing pain (Fig 2) [25]. The 10-s TCES measurements were performed 3 times each before and after the patch treatment, and the average of the 3 measurements was calculated.

Fig 1. Pyramidal thorn patch. A. The pyramidal thorn patch has a diameter of 3 cm and a thickness of 0.1 mm, and the tapered pyramidal thorn made of low-density polyethylene is 3 mm high and a square with 7-mm sides. B. Application of pyramidal thorn patches to the pain region (e.g., lower back). After palpating to determine the pain region, several pyramidal thorn patches were applied to alleviate pain.
The pain degree was calculated using the following formula: \[
\frac{(\text{pain-equivalent current} - \text{minimum perceived current})}{\text{minimum perceived current}} \times 100.
\]
For the no-Pain group, the differences between the minimum pain-evoking current and the minimum perceived current were measured before and after the patch treatment. The VAS (integer scale: 0–100) is a common pain scale for ‘so-called quantification of pain’ [26]. The VAS measurements were performed 3 times each before and after the patch treatment, and the average of the 3 measurements was calculated. We did not apply the VAS measurements to the no-Pain group because they were not experiencing pain before the patch treatment. The period between the onset of patch adhesion and the TCES and VAS measurements was about 5 min.

**NIRS oxyhemoglobin measurements**

Before and after patch treatment, NIRS (ETG-4000/OT-R40, Hitachi, Tokyo, Japan) was used to measure the relative concentration of oxyhemoglobin flow over the dorsolateral prefrontal cortex (DLPFC) and orbitofrontal cortex (OFC) (Fig 3). The period between the onset of patch adhesion and the NIRS measurement was about 10 min. The directions of the start and end of posture that produced the pain were given to the participants in the Pain group with an audio guide. The start guidance was given 30 s later after the onset of a NIRS measurement, and the end guidance was given additional 10 s later. For the no-Pain group, although no posture was taken, the same audio guide was played to eliminate the effect of the voice. NIRS channels (CH) 1 – 9 were assigned to the DLPFC, and CH10 – 22 were assigned to the OFC. During the NIRS measurements, the room temperature was maintained at 22–23°C. The room had white walls and was kept very quiet. The participants wore a sleeping mask to eliminate extra visual stimulation. Details of NIRS measurements were described previously [15]. Briefly, the NIRS optodes were placed in the proper position for each participant according to the international 10–20 system [27]. The channels between the optodes measured on the skull were assigned to brain regions using the virtual registration method [28, 29]. The DLPFC roughly corresponds with Brodmann area 46 [30], and the OFC consists of Brodmann areas 10 and 11 [31]. According to the atlas by Talairach and Tournoux [32], the upper DLPFC was assigned to CH1, 2, 3, and 4; the right DLPFC to CH10, 14; the left DLPFC to CH13, 18; the prefrontal pole to CH11,
12, 15, 16, 17; and the OFC to CH20, 21. The NIRS data were analyzed with MATLAB (2018, MathWorks, Natick, MA, USA). The sampling rate of the NIRS was 10 Hz. All NIRS data were processed using high band-pass (0.001 Hz) and low band-pass (1 Hz) filters to remove artifacts, such as heartbeat and body movements. The NIRS data were averaged using a moving average, and the values of the 3 trials were averaged. The NIRS data were normalized with Z scores for the 30-s periods between the measurement onset and the timing at which the participants sensed pain while assuming the specified pain-producing posture. This normalization allowed us to compare the changes in oxyhemoglobin levels in the specific brain regions while pain was being sensed, and minimized the contribution from the hemodynamic activity in the scalp to the NIRS data measured because its contribution is almost constant in spite of external stimuli [33]. Thus, the NIRS data were considered to represent the oxyhemoglobin levels in our results. The experiments were performed in the same manner for both groups, except the no-Pain group did not assume a posture that evoked pain.

Fig 3. Near-infrared spectroscopy (NIRS). A. A picture of a typical participant equipped with NIRS optodes. B and C. The NIRS comprised 8 elements for the NIR light emitter (red) and 7 elements for the detector (blue). The numbers indicate the channels (green) recorded. The NIRS channels were placed above the dorsolateral prefrontal cortex and the orbitofrontal cortex. The channels between the optodes measured on the skull were assigned to the brain regions using the virtual registration method.

https://doi.org/10.1371/journal.pone.0256626.g003
**ELISA for salivary oxytocin.** Before and after patch treatment, saliva was collected from all the participants in both groups. To evoke saliva secretion, the participants chewed a saliva-test gum (Oral Care, Tokyo, Japan) for 5 min. During the first 1 min, the unstimulated saliva was swallowed. The saliva secretion for the next 4 min and gum were then collected in a 50-mL tube. The tube was iced, and the saliva was dispensed in 1-mL aliquots into 1.5-mL tubes and maintained at -20˚C. Before oxytocin measurements, the saliva was centrifuged at 1500 ×g for 15 min at 4˚C, and the supernatant was diluted 10 times with the assay solution of the oxytocin ELISA kit (ADI-901-153A, Enzo Life Sciences, Farmingdale, NY, USA). The salivary oxytocin levels were measured according to the manufacturer’s instructions. This assay was a competitive ELISA [34]. After overnight incubation at 4˚C, the excess reagents were washed off and the bound oxytocin phosphatase was incubated with the substrate. After 1 h, the enzyme reaction was stopped, and the optical density was read on a microplate reader Corona Electric SH-1000 (Hitachinaka, Ibaraki, Japan) at 405 nm. The optical density was inversely proportional to the concentration of salivary oxytocin. The content (pg/mL) was determined by plotting the optical density of each sample against a standard curve. The measurement range was 15–1000 pg/mL according to the manufacturer.

**Statistical analysis**

The data are expressed as mean ± SEM or with box-and-whisker plots. Significant differences were defined as P < 0.05. Wilcoxon signed-rank test was used as a non-parametric test to compare the paired two groups. Data analysis was performed using R software version 4.10 (https://www.r-project.org/).

**Results**

**Quantitative measurements of pain relief by TCES and VAS**

For the no-Pain group, the differences between the minimum TCES current to evoke pain and the minimum TCES current to be perceived were measured before and after the patch treatment. The TCES values (i.e., ‘pain degree’ described in the Methods section) for the no-Pain group were 243.1 ± 91.7 and 202.1 ± 71.2 in these 2 trials, respectively (n = 18, Wilcoxon signed-rank test, P = 0.325, Z = 1.0, Cliff’s delta = 0.01; Fig 4A). These 2 trials corresponded to those before and after the patch treatment for the Pain group. The pain degree values, however, depended largely on the individuals, and thus the data were normalized by the first trial. The normalized values for the second trial were 96.0 ± 0.1% (i.e., those for the first trial were 100%). That is, there were no significant differences between the 2 trials (n = 18, Wilcoxon signed-rank test, P = 0.442). The VAS measurements were not applied to the no-Pain group because the participants were not experiencing pain.

For the Pain group, the TCES values (i.e., pain degree) were measured when the participants assumed the pain-evoking posture. These values decreased from 130.6 ± 28.9 to 64.5 ± 11.0 following pyramidal thorn patch treatment (n = 27, Wilcoxon signed-rank test, P = 0.005, Z = 2.8, Cliff’s delta = 0.36; Fig 4B). The normalized values for the second trial were 73.7 ± 0.5% (n = 27, Wilcoxon signed rank test, P = 0.006). The VAS values were 31.4 ± 2.9 before the pyramidal thorn patch treatment and 27.0 ± 3.4 after the treatment (n = 26). That is, the pyramidal thorn patch treatment significantly reduced the VAS values in the Pain group (n = 26, Wilcoxon signed-rank test, P = 0.027, Z = 2.2, Cliff’s delta = 0.21; Fig 4C). Thus, the TCES as well as the VAS showed a significant reduction of pain following pyramidal thorn patch treatment.
Change in oxyhemoglobin measured by NIRs

The NIRS experiments were performed in the same way for both groups, except that participants in the no-Pain group did not assume a pain-evoking posture. The oxyhemoglobin levels in the no-Pain group measured by NIRS were not significantly altered in the prefrontal cortex before and after the patch treatment (n = 18, Wilcoxon signed-rank test; Fig 5A).

In the Pain group, the oxyhemoglobin level in the left DLPFC (CH13 and 18) had a tendency to decrease after the patch treatment (n = 21, Wilcoxon signed-rank test, \( P = 0.058 \), \( Z = 1.9 \), Cliff’s delta = 0.10). Furthermore, the correlation coefficient for the left DLPFC activity between before the patch treatment (i.e., pre) and after the patch treatment (i.e., post) showed a correlation (\( r = 0.68 \)). Although NIRS data were obtained from all the participants in the Pain group (n = 27), but the NIRS data of the left DLPFC in 6 patients failed to record. The oxyhemoglobin levels in the other DLPFC regions (such as upper DLPFC (CH1, 2, 3, and 4; \( P = 0.412 \)), right DLPFC (CH10 and 14; \( P = 0.212 \)), frontal pole (CH11, 12, 15, 16, and 17; \( P = 0.390 \)), and the OFC (CH20 and 21; \( P = 0.823 \)) were not significantly altered, although there was a tendency to increase after treatment (Fig 5B and 5C). Thus, we conclude that the left DLPFC was likely to be inactivated by pain relief.

Salivary oxytocin measurements

We expected that the amount of oxytocin secreted from the posterior pituitary would increase during pain relief in participants sensing pain. To examine this, we performed 2 sets of experiments in both the no-Pain and Pain groups. For the no-Pain group, the pyramidal thorn patches (~15 patches) were applied to the shoulder for 30 min. Before and after the patch adhesion, with an interval of approximately 50 min including the 30-min period of patch adhesion, we obtained the saliva and measured the oxytocin levels by ELISA. The basal oxytocin levels were very low (i.e., before patch adhesion), and only 2 of the 13 participants without pain had oxytocin levels above the detection limit (15.0 pg/mL). The change in the oxytocin levels following patch adhesion ranged from 42% to 290%. As described above, however, the basal levels were very low, and thus the changes due to patch adhesion were not analyzed further.
Fig 5. Changes in oxyhemoglobin levels normalized with Z-score before (Pre) and after (Post) pain treatment. A. Participants without pain (no-Pain group, n = 18). No significant difference was found by Wilcoxon signed-rank test ($P = 0.325$). The DLPFC comprised the upper region, right region, left region, and frontal pole. The directions of posture were not given to the participants in no-Pain group. That is, only the effects of patch adhesion were examined before (Pre) and after (Post) patch treatment. B. Participants with pain (Pain group, n = 27). In the left DLPFC, there was a tendency of the reduction of oxyhemoglobin levels during patch treatment (n = 21, Wilcoxon signed-rank test, $P = 0.058$). This reduction was supported by the correlation coefficient ($r = 0.68$) calculated for the left DLPFC activity between before patch treatment (i.e., Pre) and after patch treatment (i.e., Post). The directions of the start and end of posture that produced the pain were given to the participants in Pain group with an audio guide. C. All the data (n = 21) recorded in the left DLPFC of the participants with pain (Pain group) before (Pre) and after (Post) pain treatment.

https://doi.org/10.1371/journal.pone.0256626.g005
We also examined the salivary oxytocin levels in the Pain group before and after patch treatment. The time difference between the 2 samplings was the same as for the no-Pain group (50-min interval including the 30-min period of patch adhesion). Among the 27 participants in the Pain group, the saliva obtained from 19 patients showed oxytocin levels within the detection range (15–1000 pg/mL). We found no significant difference in the salivary oxytocin levels before and after the patch treatment (Wilcoxon signed-rank test, \( P = 0.258 \), \( Z = 1.17 \), Cliff’s delta = 0.17; Fig 6).

Discussion

In the present study, the NIRS data suggested that the left DLPFC was inactivated by pain relief resulting from the thorn patch treatment. This finding is consistent with previous findings that compression at myofascial trigger points, known as ischemic compression, relieves musculoskeletal pain at the neck and that compression decreases the activity in the prefrontal cortex as observed by NIRS [35]. The effects of compression at myofascial trigger points are thought to be mediated by inhibitory effects on prefrontal cortex activity, i.e., inhibition of hyperactivity of the sympathetic nervous system [35]. On the other hand, suppression of the left DLPFC activity by pain relief in our study appeared to be inconsistent with findings from other studies showing that noninvasive stimulation (e.g., repetitive transcranial magnetic stimulation) of the left DLPFC effectively treats chronic pain [36–39]. Repetitive transcranial magnetic stimuli applied to the left DLPFC increases oxyhemoglobin levels in the left DLPFC [40].

Our potential explanation for the large difference between our experiments and previous experiments using repetitive transcranial magnetic stimulation is the timing of sensing pain relief in the procedures. In our experiments, we applied the patches to the pain regions and...
then recorded the oxyhemoglobin levels in the left DLPFC. In the previous experiments, however, the repetitive transcranial magnetic stimuli were applied to the left DLPFC, and then pain relief experienced by the participants was evaluated some weeks after the onset of treatment. In addition, the number of stimuli largely differed between our protocol of patch treatment and the protocol of repetitive transcranial magnetic stimulation.

Furthermore, Morikawa et al. reported that the compression at ‘non’-myofascial trigger points increased the oxyhemoglobin concentration in the prefrontal cortex [35]. That is, the effects of compression at myofascial trigger points closely resemble those of our patch treatment, whereas the effects of compression at non-myofascial trigger points may resemble those of repetitive transcranial magnetic stimulation on the prefrontal cortex. The oxyhemoglobin levels after pain treatment on the basis of repetitive transcranial magnetic stimulation have not yet been fully measured. Here, we propose that repetitive transcranial magnetic stimulation includes some effects of inactivation of the left DLPFC that have not been appropriately assessed. In the near future, we will use both transcranial magnetic stimulation and NIRS measurements to assess the left DLPFC of participants with pain, and carefully observe the changes in oxyhemoglobin levels after stimulation.

Other previous studies showed that chronic pain (e.g., chronic back pain, migraine, trigeminal neuropathic pain, hypnic headache, chronic post-traumatic headache, hip osteoarthritis, and complex regional pain syndrome) is associated with a decrease in the gray matter of the left DLPFC (probably due to neuronal loss in the left DLPFC) and that successful interventions could reverse this structural abnormality [39, 41]. In addition, on the basis of fMRI studies revealing that painful touch produces greater activation of the OFC than affectively neutral stimuli [42–44], the involvement of the OFC in pain relief should also be considered.

As can be seen in the Results section and S1 File, the P values by Wilcoxon signed-rank test for the PFC regions in Fig 5 were: $P = 0.412$ for the upper DLPFC, $P = 0.212$ for the right DLPFC, $P = 0.058$ for the left DLPFC, $P = 0.390$ for the frontal pole, and $P = 0.823$ for the OFC. Only the data of left DLPFC showed the tendency of a change (i.e., $P$ was close to 0.05), but the data obtained from the other regions did not show such a tendency because the $P$ values were over 0.2. However, in general, the involvement of DLPFC in pain is well known [39]. Seminowicz and Moayedi described that “the structure and function of the DLPFC is abnormal in some chronic pain conditions. Upon successful resolution of pain, these abnormalities are reversed” [39]. Thus, the attention to the DLPFC for pain relief is appropriate, but the further studies are needed.

As far as we know, a previous paper described that the right DLPFC was involved in the modulation of heat pain [45]. In this study, the transcranial direct current stimulation to the right DLPFC was used to examine the conditioned placebo/nocebo cue response to heat pain. On the other hand, there are many studies indicating that the left DLPFC was associated with pain processing [46–51]. At present, we do not know the detailed mechanism why the left DLPFC activity is decreased during pain relief. The structural and functional differences between the left and right DLPFC should be carefully examined in the future.

The pain degree (Fig 4A, 4B) differed between participants with or without pain. The pain degree recorded in the Pain group was obviously lower than that in the no-Pain group. We concluded that the threshold of pain sensing in the Pain group was lower than that of the minimum perceived pain in the no-Pain group. Thus, the participants with pain are considered to be more sensitive to pain that is bearable for those without pain [52, 53].

No significant difference in the salivary oxytocin levels was detected between before and after the pain relief treatment due to the varying levels of oxytocin (Fig 6). Not our team but the other research team has succeeded in detecting the change in salivary oxytocin levels during meditation using an ELISA kit [34]. In their experiments, the oxytocin levels were
measured in participant saliva before and after the meditation, and the salivary oxytocin levels were significantly increased after the meditation. Thus, the validity of the use of an oxytocin ELISA kit has been confirmed. Previous studies clearly showed that oxytocin has antinociceptive and analgesic effects [17, 18]. To achieve these effects, increased oxytocin is thought to be secreted from the posterior pituitary [54, 55]. We consider that some of the secreted oxytocin is consumed for pain relief; thus, the salivary oxytocin levels would vary widely. In addition, the metabolism of oxytocin is rapid [56]. Previous studies showed that the half-life of oxytocin in the blood and cerebrospinal fluid is 5 min and 20 min, respectively [57, 58]. Therefore, because the saliva was collected over 20 min after adhesion of the pyramidal thorn patches, it is possible that the salivary oxytocin was already metabolized at the time of the measurement.

The present results demonstrated that adhering pyramidal thorn patches on the pain region relieved pain. Here, we should consider sham experiments for patch treatment. The sham patch is a patch without a pyramidal thorn. Previous reports demonstrated that analgesic effects were achieved with sham patches, probably due to hair deflection on hairy skin [3]. Thus, the effects of sham patches were included in the pain relief by patch treatment. Furthermore, we should discuss the point that the left DLPFC might be ‘activated before the patch treatment’, because the participants could ‘expect the pain relief by the patch treatment’ [59, 60]. We cannot deny this possibility at present. This point will be examined in the next studies.

In conclusion, the degree of pain relief brought about by patch treatment was qualitatively expressed as a change in the TCES values. The region in the prefrontal cortex involved in this pain relief was the left DLPFC, which was likely to be inactivated by pain relief. The change in salivary oxytocin levels during pain relief varied, probably due to the balance between the secretion of oxytocin from the brain and the utilization of oxytocin at the pain regions. The findings of the present study suggest that the left DLPFC is a target for analgesia in the brain.

Supporting information
S1 File. This is the raw data for Figs 4–6.
(XLSX)

Acknowledgments
We thank Mayuri Namba and Yuki Totani for their support of figure drawing and statistical analysis.

Author Contributions
Conceptualization: Masashi Hori, Kotaro Oka, Fusako Koshikawa, Etsuro Ito.
Data curation: Shun Miyashiro, Yurika Yamada, Masaru Nagaoka, Rei Shima, Toshizumi Muta, Haruyuki Ishikawa, Tetsuri Abe.
Investigation: Shun Miyashiro, Yurika Yamada, Masaru Nagaoka, Rei Shima, Toshizumi Muta, Haruyuki Ishikawa, Tetsuri Abe, Etsuro Ito.
Supervision: Masashi Hori, Kotaro Oka, Fusako Koshikawa.
Validation: Etsuro Ito.
Writing – original draft: Shun Miyashiro, Etsuro Ito.
Writing – review & editing: Yurika Yamada, Masaru Nagaoka, Rei Shima, Toshizumi Muta, Haruyuki Ishikawa, Tetsuri Abe, Masashi Hori, Kotaro Oka, Fusako Koshikawa.
References

1. National Center for Complementary and Integrative Health, National Institutes of Health, USA. Use of Complementary and Integrative Health Approaches in the United States, 2012, 2016; https://www.nccih.nih.gov/about/use-of-complementary-and-integrative-health-approaches-in-the-united-states-2012 (accessed June 19, 2021).

2. Saito N, Shima R, Yamada Y, Nagaoka M, Ito E, Yoshioka T. A proposed molecular mechanism for physical analgesia in chronic pain. Neural Plast. 2018; 2018: 1260285. https://doi.org/10.1155/2018/1260285 PMID: 29887879

3. Saito N, Shima R, Yen C-T, Yang R-C, Ito E, Yoshioka T. Adhesive pyramidal thorn patches provide pain relief to athletes. Kaohsiung J Med Sci. 2019; 35: 230–237. https://doi.org/10.1002/kjm2.12044 PMID: 30887714

4. Gamal-Eltrabily M, Martínez-Lorenzana G, González-Hernández A, Condés-Lara M. Cortical modulation of nociception. Neuroscience 2021; 458: 256–270. https://doi.org/10.1016/j.neuroscience.2021.01.001 PMID: 33465410

5. Cardoso-Cruz H, Sousa M, Vieira JB, Lima D, Galhardo V. Prefrontal cortex and mediodorsal thalamus reduced connectivity is associated with spatial working memory impairment in rats with inflammatory pain. Pain 2013; 154: 2479–2491. https://doi.org/10.1007/j.pain.2013.07.020 PMID: 22626826

6. Henderson LA, Peck CC, Petersen ET, Rae CD, Youssef AM, Reeves JM, et al. Chronic pain: lost inhibition? J Neurosci. 2013; 33: 7574–7582. https://doi.org/10.1523/JNEUROSCI.0174-13.2013 PMID: 23616562

7. Jurik A, Auffenberg E, Klein S, Deussing JM, Schmid RM, Wotjak CT, et al. Roles of prefrontal cortex and paraventricular thalamus in affective and mechanical components of visceral nociception. Pain 2015; 156: 2479–2491. https://doi.org/10.1097/j.pain.000000000000318 PMID: 26262826

8. Kummer KK, Mitrić M, Kalpachidou T, Kress M. The medial prefrontal cortex as a central hub for mental comorbidities associated with chronic pain. Int J Mol Sci. 2020; 21: 3440. https://doi.org/10.3390/ijms21103440 PMID: 32414089

9. Condés-Lara M, Omaña-Zapata I, Talavera E. Facilitating action of medial prefrontal cortex upon the noxious thermally-evoked responses in thalamic centralis lateralis nucleus. J Physiol. (Paris) 1991; 85: 188–194. PMID: 1820452

10. Hadjiipavlov G, Dunckley P, Behrens TE, Tracey I. Determining anatomical connectivities between cortical and brainstem pain processing regions in humans: a diffusion tensor imaging study in healthy controls. Pain 2006; 123: 169–178. https://doi.org/10.1016/j.pain.2006.02.027 PMID: 16616418

11. Ji G, Sun H, Fu Y, Li Z, Pais-Vieira M, Galhardo V, et al. Cognitive impairment in pain through amygdala-driven prefrontal cortical deactivation. J Neurosci. 2010; 30: 5451–5464. https://doi.org/10.1523/JNEUROSCI.0225-10.2010 PMID: 20939266

12. Ong WY, Stohler CS, Herr DR. Role of the prefrontal cortex in pain processing. Mol Neurobiol. 2019; 56: 1137–1166. https://doi.org/10.1007/s12035-018-1130-9 PMID: 29767878

13. Onozawa K, Yagasaki Y, Izawa Y, Abe H, Kawakami Y. Amygdala-prefrontal pathways and the dopamine system affect nociceptive responses in the prefrontal cortex. BMC Neurosci. 2011; 12: 115. https://doi.org/10.1186/1471-2202-12-115 PMID: 22085449

14. Brazy JE. Near-infrared spectroscopy. Clin Perinatol. 1991; 18: 519–534. https://doi.org/10.1016/S0095-5108(18)30501-7 PMID: 1657489

15. Miyashiro S, Yamada Y, Muta T, Ishikawa H, Abe T, Hori M, et al. Activation of the orbitofrontal cortex by both meditation and exercise: a near-infrared spectroscopy study. PLoS ONE 2021; 16: e0247685. https://doi.org/10.1371/journal.pone.0247685 PMID: 33621250

16. Lee CH, Sugiyama T, Kataoka A, Kudo A, Fujino F, Chen YW, et al. Analysis for distinctive activation patterns of pain and itch in the human brain cortex measured using near infrared spectroscopy (NIRS). PLoS One 2013; 8: e75360. https://doi.org/10.1371/journal.pone.0075360 PMID: 24098375

17. Tracy LM, Georgiou-Karistianis N, Gibson SJ, Giannarou MJ. Oxytocin and the modulation of pain experience: Implications for chronic pain management. Neurosci Biobehav Rev. 2015; 55: 53–67. https://doi.org/10.1016/j.neubiorev.2015.04.013 PMID: 25956252

18. Grinevich V, Charlet A. Oxytocin: pain relief in skin. Pain 2017; 158: 2061–2063. https://doi.org/10.1097/j. pain.0000000000001006 PMID: 28777772

19. Ito E, Shima R, Yoshioka T. A novel role of oxytocin: oxytocin-induced well-being in humans. Biophys. Physicobiol. 2019; 16: 132–139. https://doi.org/10.2142/biophysico.16.0_132 PMID: 3168203

20. Dale HH. On some physiological actions of ergot. J Physiol. 1906; 34: 163–206. https://doi.org/10.1113/jphysiol.1906.sp001148 PMID: 16992821
21. Landgraf R, Neumann ID. Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication. Front Neuroendocrinol. 2004; 25: 150–176. https://doi.org/10.1016/j.yfrne.2004.05.001 PMID: 15588267

22. Sivukhina EV, Jirikowski GF. Magnocellular hypothalamic system and its interaction with the hypothalamo-pituitary-adrenal axis. Steroids 2016; 111: 21–28. https://doi.org/10.1016/j.steroids.2016.01.008 PMID: 26827626

23. Yang J. Intrathecal administration of oxytocin induces analgesia in low back pain involving the endogenous peptide system. Spine (Phila Pa 1976) 1994; 19: 867–871. https://doi.org/10.1097/00007632-199404150-00001 PMID: 8009342

24. Goodin BR, Ness TJ, Robbins MT. Oxytocin—a multifunctional analgesic for chronic deep tissue pain. Curr Pharm Des. 2015; 21: 906–913. https://doi.org/10.2174/1381612820666141027111843 PMID: 25345612

25. Hasegawa J, Sugiyama D, Kumasaka M, Hishinuma M, Matsuo K, Ide S, et al. Evaluation of pain treatment by Pain Vision. J Jpn Soc Pain Clin. 2008; 15: 144–149. https://doi.org/10.11321/jjspc.07-0020

26. Sinha S, Schreiner AJ, Biernaskie J, Nickerson D, Gabriel VA. Treating pain on skin graft donor sites: Review and clinical recommendations. J Trauma Acute Care Surg. 2017; 83: 954–964. https://doi.org/10.1097/TA.0000000000001615 PMID: 28598907

27. Okamoto M, Dan H, Sakamoto K, Takeo K, Shimizu K, Kohno S, et al. Three-dimensional probabilistic anatomical crano-cerebral correlation via the international 10–20 system oriented for transcranial functional brain mapping. NeuroImage 2004; 21: 99–111. https://doi.org/10.1016/j.neuroimage.2003.08.026 PMID: 14741647

28. Rorden C, Brett M. Stereotaxic display of brain lesions. Behav Neurol. 2000; 12: 191–200. https://doi.org/10.1155/2000/421719 PMID: 11568431

29. Tsuzuki D, Jurcak V, Singh AK, Okamoto M, Watanabe E, Dan I. Virtual spatial registration of standalone FNIRS data to MNI space. NeuroImage 2007; 34: 1506–1518. https://doi.org/10.1016/j.neuroimage.2006.10.043 PMID: 17207638

30. Petralia MC, Ciurleo R, Saraceno A, Pennisi M, Basile MS, Fagone P, et al. Meta-analysis of transcriptomic data of dorsolateral prefrontal cortex and of peripheral blood mononuclear cells identifies altered pathways in schizophrenia. Genes 2020; 11: 390. https://doi.org/10.3390/genes11040390 PMID: 32260267

31. Kringelbach ML. The orbitofrontal cortex: linking reward to hedonic experience. Nat Rev Neurosci. 2005; 6: 691–702. https://doi.org/10.1038/nrn1747 PMID: 16136173

32. Talairach J, Tournoix P. Co-planar stereotactic atlas of the human brain. 1988; Thieme, New York, USA. https://doi.org/10.1016/0028-3932(88)90040-1 PMID: 3129671

33. Moriguchi Y, Noda T, Nakayashiki K, Takata Y, Setoyama S, Kawasaki S, et al. Validation of brain-derived signals in near-infrared spectroscopy through multivoxel analysis of concurrent functional magnetic resonance imaging. Hum. Brain Mapp. 2017; 38: 5274–5291. https://doi.org/10.1002/hbm.23734 PMID: 28722337

34. Machida S, Sunagawa M, Takahashi T. Oxytocin release during the meditation of altruism and appreciation (Arigato-Zen). Int J Neurol Res. 2018; 4: 364–370. https://doi.org/10.17554/j.issn.2313-5611.2018.04.75

35. Morikawa Y, Takamoto K, Nishimaru H, Taguchi T, Urakawa S, Sakai S, et al. Compression at myofascial trigger point on chronic neck pain provides pain relief through the prefrontal cortex and autonomic nervous system: a pilot study. Front Neurosci. 2017; 11: 186. https://doi.org/10.3389/fnins.2017.00186 PMID: 28442967

36. Reid P, Pridmore S. Improvement in chronic pain with transcranial magnetic stimulation. Aust N Z J Psychiatry 2001; 35: 252. https://doi.org/10.1046/j.1440-1614.2001.08848.x PMID: 11284914

37. Brighina F, Piazza A, Vitello G, Aloisio A, Palermo A, Daniele O, et al. rTMS of the prefrontal cortex in the treatment of chronic migraine: a pilot study. J Neurol Sci. 2004; 227: 67–71. https://doi.org/10.1016/j.jns.2004.08.008 PMID: 15546593

38. Graff-Guerrero A, González-Olvera J, Fresán A, Gómez-Martín D, Méndez-Núñez JC, Pellicer F. Repetitive transcranial magnetic stimulation of dorsolateral prefrontal cortex increases tolerance to human experimental pain. Brain Res Cogn Brain Res. 2005; 25: 153–160. https://doi.org/10.1016/j.cogbrainres.2005.05.002 PMID: 15935625

39. Seminowicz DA, Moayed M. The dorsolateral prefrontal cortex in acute and chronic pain. J Pain 2017; 18: 1027–1035. https://doi.org/10.1016/j.jpain.2017.03.008 PMID: 28400293

40. Thomson RH, Cleve TJ, Bailey NW, Rogasch NC, Maller JJ, Daskalakis ZJ, et al. Blood oxygenation changes modulated by coil orientation during prefrontal transcranial magnetic stimulation. Brain Stimul. 2013; 6: 576–581. https://doi.org/10.1016/j.brs.2012.12.001 PMID: 23376041
41. Davis KD, Moayedi M. Central mechanisms of pain revealed through functional and structural MRI. J Neuroimmunol. 2013; 8: 518–534. https://doi.org/10.1016/j.jneuroim.2013.05.013 PMID: 23852710

42. Rolls ET, O’Doherty J, Kringelbach ML, Francis S, Bowell R, McGlone F. Representations of pleasant and painful touch in the human orbitofrontal and cingulate cortices. Cereb Cortex 2003; 13: 308–317. https://doi.org/10.1093/cercor/13.3.308 PMID: 12571120

43. Stalnaker TA, Cooch NK, Schoenbaum G. What the orbitofrontal cortex does not do. Nat Neurosci. 2015; 18: 620–627. https://doi.org/10.1038/nn.3962 PMID: 25919962

44. Urien L, Wang J. Top-down cortical control of acute and chronic pain. Psychosom Med. 2019; 81: 851–858. https://doi.org/10.1097/PSY.0000000000000744 PMID: 31609921

45. Egorova N, Yu R, Kaur N, Vangel M, Gollub RL, Dougherty DD, et al. Neuromodulation of conditioned placebo/nocebo in heat pain: anodal vs cathodal transcranial direct current stimulation to the right dorsolateral prefrontal cortex. Pain 2015; 156: 1342–1347. https://doi.org/10.1097/j.pain.000000000000163 PMID: 25806605

46. Mariano TY, Van’t Wout M, Garnaat SL, Rasmussen SA, Greenberg BD. Transcranial direct current stimulation (tDCS) targeting left dorsolateral prefrontal cortex modulates task-induced acute pain in healthy volunteers. Pain Med. 2016; 17: 737–745. https://doi.org/10.1093/pm/pnv042 PMID: 26814276

47. Silva AF, Zrotea M, Carvalho S, Leite J, Torres IL, Fregni F, et al. Anodal transcranial direct current stimulation over the left dorsolateral prefrontal cortex modulates attention and pain in fibromyalgia: randomized clinical trial. Sci Rep. 2017; 7: 135. https://doi.org/10.1038/s41598-017-00185-w PMID: 28273933

48. Delidar Z, Rustomov N, Bois S, Blanchette I, Piché M. Enhancement of pain inhibition by working memory with anodal transcranial direct current stimulation of the left dorsolateral prefrontal cortex. J Physiol Sci. 2018; 68: 825–836. https://doi.org/10.1007/s12576-018-0598-4 PMID: 29450801

49. Seminowicz DA, de Martino E, Schabrun SM, Graven-Nielsen T. Left dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation reduces the development of long-term muscle pain. Pain 2018; 159: 2486–2492. https://doi.org/10.1016/j.pain.2018.06.007 PMID: 30431520

50. De Martino E, Seminowicz DA, Schabrun SM, Petrini L, Graven-Nielsen T. High frequency repetitive transcranial magnetic stimulation to the left dorsolateral prefrontal cortex modulates sensorimotor cortex function in the transition to sustained muscle pain. Neuroimage 2019; 186: 93–102. https://doi.org/10.1016/j.neuroimage.2018.10.076 PMID: 30391344

51. De Martino E, Fernandes AM, Galhardoni R, De Oliveira Souza C, Ciampi De Andrade D, Graven-Nielsen T. Sessions of prolonged continuous theta burst stimulation or high-frequency 10 Hz stimulation to left dorsolateral prefrontal cortex for 3 days decreased pain sensitivity by modulation of the efficacy of conditioned pain modulation. J Pain 2019; 20: 1459–1469. https://doi.org/10.1016/j.jpain.2019.05.010 PMID: 31132509

52. Imamura M, Chen J, Matsubayashi SR, Targino RA, Aflieri FM, Bueno DK, et al. Changes in pressure pain threshold in patients with chronic nonspecific low back pain. Spine (Phila Pa 1976) 2013; 38: 2098–2107. https://doi.org/10.1097/BRS.0b013e3182947700 PMID: 24026153

53. Kato F, Abe T, Kanbara K, Ban I, Kiba T, Kawashima S, et al. Pain threshold reflects psychological traits in patients with chronic pain: a cross-sectional study. Biopsychosoc Med. 2017; 11: 13. https://doi.org/10.1186/s12967-017-00163 PMID: 28507394

54. Gravius N, Chaudhry SR, Muhammad S, Boström A, Gravius S, Randau T, et al. Selective L4 dorsal root ganglion stimulation evokes pain relief and changes of inflammatory markers: Part I Profiling of saliva and serum molecular patterns. Neuromodulation 2019; 22: 44–52. https://doi.org/10.1111/ner.12866 PMID: 30358008

55. Kinfe TM, Asif M, Chakravarty KV, Deer TR, Kramer JM, Yearwood TL, et al. Unilateral L4-dorsal root ganglion stimulation evokes pain relief in chronic neuropathic postsurgical knee pain and changes of inflammatory markers: Part II Whole transcriptome profiling. J Transl Med. 2019; 17: 205. https://doi.org/10.1186/s12967-019-1952-x PMID: 31217010

56. Hilfinger L, Zhao Q, Kersperr D, Inquimbert P, Andry V, Goumon Y, et al. A nonpeptide oxytocin receptor agonist for a durable relief of inflammatory pain. Sci Rep. 2020; 10: 3017. https://doi.org/10.1038/s41598-020-59929-w PMID: 32080303

57. Mens WB, Witter A, van Wimersma Greidanus TB. Penetration of neurohypophyseal hormones from plasma into cerebrospinal fluid (CSF): half-times of disappearance of these neuropeptides from CSF. Brain Res. 1983; 262: 143–149. https://doi.org/10.1016/0006-8993(83)90478-x PMID: 6831225

58. Morin V, Del Castillo JRE, Authier S, Ybarra N, Otis C, Gauvin D, et al. Evidence for non-linear pharmacokinetics of oxytocin in anesthetized [sic] rat. J Pharm Sci. 2008; 11: 12–24. https://doi.org/10.18433/3pk5x PMID: 19183510
59. Wager TD, Rilling JK, Smith EE, Sokolik A, Casey KL, Davidson RJ, et al. Placebo-induced changes in FMRI in the anticipation and experience of pain. Science 2004; 303: 1162–1167. https://doi.org/10.1126/science.1093065 PMID: 14976306

60. Zeng Y, Hu D, Yang W, Hayashinaka E, Wada Y, Watanabe Y, et al. A voxel-based analysis of neurobiological mechanisms in placebo analgesia in rats. Neuroimage 2018; 178: 602–612. https://doi.org/10.1016/j.neuroimage.2018.06.009 PMID: 29883731